NCT04953312 2026-03-12
CALPRO
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
Clinical Trials
16 trialsNCT04565665 2026-03-10
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05672355 2026-03-05
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 2 Recruiting
NCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT05102656 2025-11-17
Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05655546 2025-08-08
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
Phase NA Terminated
NCT04347226 2025-05-22
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Columbia University
Phase 2 Terminated
NCT05386355 2025-03-11
MoVeUP
IDeA States Pediatric Clinical Trials Network
Phase NA Completed
NCT05135650 2025-02-13
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT05465876 2024-04-04
PACE-CLL
Sunnybrook Health Sciences Centre
Phase 2 Withdrawn
NCT05438498 2023-09-08
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
MediMergent, LLC
Phase 3 Terminated
NCT05393999 2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2 Withdrawn
NCT04951323 2022-05-18
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
University of Liege
Phase 3 Unknown
NCT04419623 2021-05-12
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Telios Pharma, Inc.
Phase 1 Completed
NCT04392128 2020-09-04
HYACINTHE
Institut de cancérologie Strasbourg Europe
Phase 2 Withdrawn